Inactive Instrument

Adamas Pharmaceuticals, Inc.

Equities

ADMS

US00548A1060

Biotechnology & Medical Research

Adamas Pharmaceuticals, Inc. Provides Revenues Guidance for the Fourth Quarter and Full Year 2020

January 13, 2021 at 09:27 am EST

Adamas Pharmaceuticals, Inc. provided revenues guidance for the fourth quarter and full year 2020. Total revenues for the fourth quarter of 2020 are anticipated to be $20.8 million, a 27% increase over the $16.3 million recorded in the fourth quarter of 2019. Full year total revenues are expected to be $74.2 million for 2020, compared to $54.6 million for 2019, a 36% increase.

Latest news about Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc. Announces Management Changes	21-11-24	CI
Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from NASDAQ Composite Index	21-11-24	CI
Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from S&P TMI Index	21-11-24	CI
Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from S&P Global BMI Index	21-11-24	CI
Supernus Pharmaceuticals, Inc. completed the acquisition of Adamas Pharmaceuticals, Inc. from Mohr Davidow Ventures and others.	21-11-23	CI
Northland Downgrades Adamas Pharmaceuticals to Market Perform From Outperform; Price Target is $8.50	21-11-17	MT
Adamas Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
North American Morning Briefing : Stock Futures -3-	21-10-13	DJ
ADAMAS PHARMACEUTICALS : SVB Leerink Downgrades Adamas Pharmaceuticals to Market perform From Outperform, Adjusts Price Target to $8 From $6	21-10-12	MT
ADAMAS PHARMACEUTICALS : JMP Securities Downgrades Adamas Pharmaceuticals to Market Perform from Market Outperform	21-10-12	MT
ADAMAS PHARMACEUTICALS : Piper Sandler Downgrades Adamas Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $8 from $7	21-10-12	MT
ADAMAS PHARMACEUTICALS : HC Wainwright Downgrades Adamas Pharmaceuticals to Neutral From Buy, Trims Price Target to $9.10 From $10	21-10-12	MT
DJ Industrial : US Stocks Drop Monday as Markets Await Big Bank Earnings; Oil Price Advances	21-10-11	MT
Close Update: US Stocks Reverse Earlier Gains as Markets Await Big Bank Earnings; Oil Price Advances	21-10-11	MT
Flexion Therapeutics : Health Care Stocks Sliding in Late Monday Trading	21-10-11	MT
Adamas Pharmaceuticals : Health Care Stocks Drifting Monday as Biotechs Climb	21-10-11	MT
NASDAQ 100 : Top Midday Gainers	21-10-11	MT
DJ Industrial : Equities Stall Midday as Oil Prices Claim Fresh Seven-Year Highs	21-10-11	MT
Midday Report: US Stocks Stall as Oil Prices Claim Fresh Seven-Year Highs	21-10-11	MT
Sector Update: Health Care	21-10-11	MT
ADAMAS PHARMACEUTICALS : William Blair Downgrades Adamas Pharmaceuticals to Market Perform From Outperform	21-10-11	MT
Supernus Pharmaceuticals : to Buy Adamas for $400 Million Upfront Plus Further Boost Based on Parkinson's Disease Drug Sales	21-10-11	MT
Protagonist Therapeutics : Health Care Stocks Trade Lower Premarket Monday	21-10-11	MT
DJ Industrial : Wall Street Declines on Soaring Energy Prices	21-10-11	MT
DJ Industrial : Top Premarket Gainers	21-10-11	MT

Chart Adamas Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company's portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson's disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer's type.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+26.37%	44.96B
IQVIA HOLDINGS INC.	-1.01%	42.65B
LONZA GROUP AG	+46.00%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B
BIO-TECHNE CORPORATION	+6.23%	12.75B
MEDPACE HOLDINGS, INC.	+26.99%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B

Other Biotechnology & Medical Research